Xeris Biopharma Holdings, Inc.
XERS
$8.48
-$0.05-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -17.17M | 12.01M | 554.00K | -15.64M | -32.00M |
| Total Depreciation and Amortization | 12.81M | 12.76M | 12.69M | 12.63M | 12.56M |
| Total Amortization of Deferred Charges | 3.51M | 3.42M | 3.37M | 3.33M | 3.29M |
| Total Other Non-Cash Items | 58.90M | 22.06M | 22.37M | 20.70M | 15.89M |
| Change in Net Operating Assets | -1.44M | -1.72M | -10.36M | -10.46M | -15.92M |
| Cash from Operations | 56.61M | 48.53M | 28.63M | 10.56M | -16.18M |
| Capital Expenditure | -938.00K | -1.01M | -696.00K | -583.00K | -599.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 10.24M | 20.24M |
| Cash from Investing | -938.00K | -1.01M | -696.00K | 9.65M | 19.64M |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | 11.83M |
| Issuance of Common Stock | 25.92M | 25.58M | 22.27M | 21.56M | 7.23M |
| Repurchase of Common Stock | -19.23M | -19.90M | -10.88M | -9.50M | -9.11M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | -11.83M |
| Cash from Financing | 6.69M | 5.69M | 11.39M | 12.05M | -1.88M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 62.36M | 53.21M | 39.32M | 32.26M | 1.58M |